Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.
see ASCO20 Meeting Library website for more
Publications
Knowledge Background
A novel standard to evaluate the impact of therapeutic agents on patient safety – The BURDEN OF THERAPY™©∗
Paper published in Contemporary Clinical Trials Communications, Volume 4, 15 Dec 2016, Pages 186-191
Presentation at BioConclave 2016
Please find the presentation below.